# EDGAR Filing Document

**Accession Number:** 0001960154
**File Stem:** 0001214659-23-000521
**Filing Date:** 2023-1
**Character Count:** 8566
**Document Hash:** d44f08b0e7218f2c531b4915f8279bef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-23-000521.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001214659-23-000521

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230101

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Jung Cassie
- **CENTRAL INDEX KEY:** 0001960154

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38599
- **FILM NUMBER:** 23523643

**MAIL ADDRESS:**
- **STREET 1:** C/O AQUESTIVE THERAPEUTICS, INC.
- **STREET 2:** 30 TECHNOLOGY DRIVE
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aquestive Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001398733
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 208623253
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 30 TECHNOLOGY DRIVE
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059
- **BUSINESS PHONE:** 908-941-1900

**MAIL ADDRESS:**
- **STREET 1:** 30 TECHNOLOGY DRIVE
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MonoSol Rx, Inc.
- **DATE OF NAME CHANGE:** 20070507

## Ex-24

```
<pre>
      POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints
each of Lori J. Braender, A. Ernest Toth, Jr., Valerie Borchevsky and Ellen S.
Knarr, signing singly, the undersigned's true and lawful attorney-in-fact to:
(i) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer of Aquestive Therapeutics, Inc. (the "Company"), a Form ID,
including updates thereto, and Forms 3, 4, and 5 in accordance with Section
16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (ii) do
and perform any and all acts for and on behalf of the undersigned which may be
necessary or desirable to complete and execute any such Form ID, including
updates thereto, or Form 3, 4, or 5 and timely file such form with the United
States Securities and Exchange Commission and any stock exchange or similar
authority; and (iii) take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by such attorney-in-fact on behalf
of the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of this power of
attorney and the rights and powers herein granted.  The undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in such capacity at the request
of the undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 22nd day of December, 2022.

/s/ Cassie Jung
___________________________
Cassie Jung
    </pre>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Jung Cassie<br><sub>(Last) (First) (Middle)</sub><br>C/O AQUESTIVE THERAPEUTICS, INC.<br>30 TECHNOLOGY DRIVE<br><sub>(Street)</sub><br>WARREN, NJ 07059<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Aquestive Therapeutics, Inc. [ AQST ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_SVP, Operations_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 36747<sup>(1)(2)</sup> | D |  |
| Common Stock | 2000 | I | By spouse |
| Common Stock | 44 | I | By spouse IRA |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Non-Qualified Stock Option (right to buy) | <sup>(3)</sup> | 2029-08-09 | Common Stock | 25000 | $3.84 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(4)</sup> | 2030-05-12 | Common Stock | 21000 | $5.69 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(5)</sup> | 2031-06-10 | Common Stock | 18750 | $4.07 | D |  |
| Non-Qualified Stock Option (right to buy) | <sup>(6)</sup> | 2032-08-05 | Common Stock | 25000 | $0.88 | D |  |

---

### Footnotes:

(1) Includes 4,567 shares acquired pursuant to the Company's employee stock purchase plan.

(2) Includes 15,000 restricted stock units ("RSUs"), which are scheduled to vest as follows: 3,750 on March 10, 2023, 3,750 on March 10, 2024 and 7,500 on March 10, 2025.

(3) Grant of non-qualified stock options, of which 25% vested on August 9, 2020, 25% vested on August 9, 2021, and 50% vested on August 9, 2022.

(4) Grant of non-qualified stock options, of which 25% vested on May 12, 2021, 25% vested on May 12, 2022, and 50% are scheduled to vest on May 12, 2023.

(5) Grant of non-qualified stock options, of which 25% vested on June 10, 2022, 25% are scheduled to vest on June 10, 2023, and 50% are scheduled to vest on June 10, 2024.

(6) Grant of non-qualified stock options, which are scheduled to vest as follows: 25% on August 5, 2023, 25% on August 5, 2024, and 50% on August 5, 2025.

**Remarks:**
Exhibit List Exhibit 24 -- Power of Attorney

**Signature:** /s/ Lori Braender, as Attorney-In-Fact  
**Date:** 2023-01-11

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**